Efficacy of D0870 treatment of experimental Candida vaginitis
- PMID: 9210665
- PMCID: PMC163939
- DOI: 10.1128/AAC.41.7.1455
Efficacy of D0870 treatment of experimental Candida vaginitis
Abstract
In this study, oral administration of the triazole D0870 was compared to oral administration of fluconazole in the treatment of experimental vaginal candidiasis. With an estrogen-dependent murine model of Candida albicans vaginal infection, the effects of D0870 on several isolates, including fluconazole-susceptible and -resistant isolates, were tested. D0870, at doses of 0.5 and 2.5 mg/kg of body weight given once over the course of a 10-day infection, was effective in eradicating vaginitis caused by fluconazole-susceptible laboratory and clinical isolates, respectively. In contrast, a stricter treatment regimen (every 24 to 48 h) with 10 and 25 mg of fluconazole per kg was required to achieve similar reductions in vaginal fungal titers induced by the same isolates. Whereas fluconazole was consistently ineffective in infections induced by fluconazole-resistant isolates, as predicted by in vitro susceptibility tests, D0870 was effective, although a daily regimen of 25 mg/kg was required. Additional studies showed that despite the in vitro activity of D0870 against two clinical Candida glabrata isolates, neither D0870 nor fluconazole was effective at daily doses as high as 100 and 125 mg/kg, respectively. Taken together, although D0870 failed to show efficacy against experimental C. glabrata vaginitis, D0870 was superior to fluconazole in the treatment of experimental C. albicans vaginitis caused by isolates that were either susceptible or resistant to fluconazole.
Similar articles
-
Fluconazole, D0870, and flucytosine treatment of disseminated Candida tropicalis infections in mice.Antimicrob Agents Chemother. 1995 Apr;39(4):924-9. doi: 10.1128/AAC.39.4.924. Antimicrob Agents Chemother. 1995. PMID: 7785997 Free PMC article.
-
Treatment of HIV-related fluconazole-resistant oral candidosis with D0870, a new triazole antifungal.AIDS. 1998 Mar 5;12(4):411-6. doi: 10.1097/00002030-199804000-00010. AIDS. 1998. PMID: 9520171 Clinical Trial.
-
Antifungal activity of D0870 against murine infections and its mechanism of action.Chemotherapy. 1998 Mar-Apr;44(2):112-20. doi: 10.1159/000007102. Chemotherapy. 1998. PMID: 9551242
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
Antifungal drug resistance in pathogenic fungi.Med Mycol. 1998;36 Suppl 1:119-28. Med Mycol. 1998. PMID: 9988500 Review.
Cited by
-
Evaluation of Mucoadhesive Gels with Propolis (EPP-AF) in Preclinical Treatment of Candidiasis Vulvovaginal Infection.Evid Based Complement Alternat Med. 2013;2013:641480. doi: 10.1155/2013/641480. Epub 2013 Aug 7. Evid Based Complement Alternat Med. 2013. PMID: 23997797 Free PMC article.
-
An Update on Candida tropicalis Based on Basic and Clinical Approaches.Front Microbiol. 2017 Oct 13;8:1927. doi: 10.3389/fmicb.2017.01927. eCollection 2017. Front Microbiol. 2017. PMID: 29081766 Free PMC article. Review.
-
Repeated vulvovaginal fungal infections cause persistent pain in a mouse model of vulvodynia.Sci Transl Med. 2011 Sep 21;3(101):101ra91. doi: 10.1126/scitranslmed.3002613. Sci Transl Med. 2011. PMID: 21937756 Free PMC article.
-
An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis.Infect Immun. 2004 May;72(5):2939-46. doi: 10.1128/IAI.72.5.2939-2946.2004. Infect Immun. 2004. PMID: 15102806 Free PMC article.
-
Current and emerging azole antifungal agents.Clin Microbiol Rev. 1999 Jan;12(1):40-79. doi: 10.1128/CMR.12.1.40. Clin Microbiol Rev. 1999. PMID: 9880474 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical